• Applied Protocols with Recombinant Human Oncostatin M

  2026-05-22

  Leverage Recombinant Human Oncostatin M (rh-Oncostatin M) for robust and reproducible cytokine-driven assays across cell proliferation, differentiation, and cytokine release studies. This article delivers workflow optimization, troubleshooting insights, and direct protocol enhancements using APExBIO’s tag-free, lyophilized cytokine for advanced research reliability.

• QPRT Promotes Breast Cancer Invasion via P2Y11-Myosin Pathwa

  2026-05-22

  The reference study uncovers how quinolinate phosphoribosyltransferase (QPRT) enhances breast cancer cell invasiveness by promoting myosin light chain phosphorylation through P2Y11 receptor-mediated signaling. These findings highlight a novel axis in tumor progression, with implications for targeting purinergic signaling in cancer research.

• ERAD-Hijacking ERADECs Enable Selective Degradation of TM Pr

  2026-05-21

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that harnesses ER-associated degradation for efficient, targeted elimination of transmembrane proteins. This approach overcomes prior limitations of TPD strategies, enabling potent and selective membrane protein degradation with broad implications for therapeutic and research applications.

• HATU in Peptide Synthesis Chemistry: Protocols, Pitfalls, an

  2026-05-21

  HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) stands out for rapid, high-yield amide and ester bond formation in peptide synthesis chemistry. This article delivers workflow-anchored guidance, expert troubleshooting, and practical insights that translate complex bench research into actionable protocols.

• NSAID Effects on Canine Osteosarcoma Cell Viability In Vitro

  2026-05-20

  This study rigorously evaluates the cytotoxicity of deracoxib and piroxicam on canine osteosarcoma cell lines, revealing differential potency and a lack of apoptosis induction at cytotoxic doses. The findings clarify the potential and limitations of NSAID application in veterinary oncology models and provide a basis for integrin-targeted research strategies.

• Kaempferol Modulates NF-κB/PTGS2 to Protect Melanocytes from

  2026-05-20

  This study establishes a mechanistic link between inflammatory NF-κB/PTGS2 signaling and oxidative stress-induced ferroptosis in vitiligo melanocytes. Using an RSL3-based ferroptosis model, the paper demonstrates that kaempferol confers robust protection by suppressing this axis, providing a new framework for understanding and potentially mitigating melanocyte loss in vitiligo.

• Deracoxib and Piroxicam Effects on Canine Osteosarcoma Cells

  2026-05-19

  This study evaluates the cytotoxic effects of deracoxib and piroxicam on canine osteosarcoma cell lines in vitro. The findings highlight differential drug potencies, limited induction of apoptosis, and emphasize the need for more targeted approaches in tumor viability research.

• Catalpol: Translational Bridges from Molecular Mechanisms to

  2026-05-19

  Explore how Catalpol's multi-target actions enable precision assay design and pathway dissection in neuroprotection, osteoporosis, and fibrotic models. This in-depth review delivers new practical insights for researchers using Catalpol.

• Myeloid Tet2-IL-1β Axis Modulates Enterochromaffin Cell Diff

  2026-05-18

  Sharma et al. reveal that myeloid-specific loss of TET2 limits intestinal inflammation by increasing IL-1β, which disrupts neuronal signals that drive enterochromaffin (EC) cell differentiation and serotonin production. This neuro-immune-epithelial circuit provides new mechanistic insight into colitis regulation and highlights stress-induced catecholaminergic signaling as a key disease modulator.

• Ouabain: Selective Na+/K+-ATPase Inhibitor in Cardiovascular

  2026-05-18

  Ouabain, sourced from APExBIO, is the benchmark selective Na+/K+-ATPase inhibitor for dissecting ion transport and cardiovascular physiology in both cell and animal models. This article provides detailed protocols, advanced use-cases, and troubleshooting strategies, grounded in the latest research and comparative workflows.

• HATU in Peptide Synthesis Chemistry: Workflow & Troubleshoot

  2026-05-17

  HATU enables unparalleled efficiency in peptide synthesis chemistry by streamlining amide bond formation through its robust activation mechanism. This in-depth guide covers applied protocols, evidence-driven troubleshooting, and advanced use-cases—empowering researchers to maximize yields and reproducibility with APExBIO’s trusted reagent.

• MK-4827 (Niraparib): Precision PARP Inhibition in Cancer Res

  2026-05-16

  MK-4827 (Niraparib) is a highly selective PARP-1/-2 inhibitor that impairs DNA repair, demonstrating potent efficacy in BRCA-mutant cancer cell models. Its mechanistic selectivity and oral bioavailability support advanced research in DNA damage repair inhibition and combination therapy strategies.

• HOBt in Advanced Amide Synthesis: Mechanistic Precision & Ne

  2026-05-15

  Explore how HOBt (1-Hydroxybenzotriazole) empowers next-generation amide bond formation and peptide synthesis. This article delivers a mechanistic deep dive, practical protocol insights, and bridges to emerging applications, setting it apart from standard workflows.

• Cyclo (-RGDfC): Precision Tools for Integrin-Mediated Assays

  2026-05-15

  Cyclo (-RGDfC) advances tumor targeting and angiogenesis workflows by leveraging αvβ3 integrin specificity and superior cyclic peptide stability. This guide translates recent experimental findings and best practices into actionable steps and troubleshooting strategies for robust, reproducible results.

• 3X (DYKDDDDK) Peptide: Accelerating Translational Immuno-Onc

  2026-05-14

  This article delivers a mechanistic and strategic perspective on how the 3X (DYKDDDDK) Peptide empowers translational researchers investigating immune regulation and protein dynamics in cancer. By bridging advanced epitope tagging with emerging tumor-intrinsic mechanisms such as SLC25A1-driven PD-L1 regulation, we reveal best practices and innovations for affinity purification, immunodetection, and structural biology, with actionable protocol parameters and a critical outlook on the evolving landscape.

15780 records 1/1052 page Next 12345 下5页 Last page